Herting, Frank
Roche Diagnostics GmbH, Penzberg, Germany
3 papers on CoChat
Most cited papers
- Verified
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 366
- Verified
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research
Angiogenesis and VEGF in CancerMonoclonal and Polyclonal Antibodies Research
Cited by 201
- Verified
Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab
Bittner, B., Richter, W., Hourcade-Potelleret, F., Herting, F., & Schmidt, J. (2014) · Drug Research
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 32
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free